Storm Therapeutics
Discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME) for oncology and other diseases
STORM Therapeutics (STORM) is a clinical stage biotechnology company developing novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first-mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first-in-class small-molecule drug candidates for potential use in oncology, inflammation, viral infection and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor, STC-15, which is currently in clinical development. STC-15 represents the first ever RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional programs are planned for advancement into IND-track activities.
Fierce Biotech named STORM as one of its 2022 “Fierce 15”, designating it as one of the most innovative, exciting biotechnology companies in the industry, pioneering novel drug targets.
